SINGAPORE - Catalist-listed QT Vascular announced on Wednesday that that the US Patent and Trademark Office has issued allowance letters for four fundamental patents critical to its portfolio of specialty balloons for the treatment of vascular disease in coronary and peripheral vessels.

Three of the patents cover the group's flagship platform, Chocolate, while the fourth patent covers the Group's Glider family of products.

"To receive four key patents allowances within a short span of time is truly an exceptional experience for a start-up company" said Dr Eitan Konstantino, chief executive officer of QT Vascular.

A notice of allowance is issued by US patent authority to indicate that it believes an invention qualifies for a patent. However, the recipient is not fully protected until completion of the rest of the patent process and payment of fees.